- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01445691
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas
The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When the investigators remove the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red under blue light. This may make it easier for your doctor to take out all of the tumor from your brain. The purpose of this study is to:
- Make sure that 5-ALA helps the doctor remove more of the tumor.
- Make sure 5-ALA does not cause any side effects.
If you do not want to participate in this study, your doctor(s) will still do their best to remove all of the tumor in your brain. Whether or not you join this study will not change your treatment for your brain tumor.
Study Overview
Status
Conditions
- Glioblastoma
- Brain Cancer
- Brain Tumors
- Brain Tumor, Recurrent
- Benign Neoplasms, Brain
- Brain Neoplasms, Benign
- Brain Neoplasms, Malignant
- Brain Tumor, Primary
- Intracranial Neoplasms
- Neoplasms, Brain
- Neoplasms, Intracranial
- Primary Brain Neoplasms
- Primary Malignant Brain Neoplasms
- Primary Malignant Brain Tumors
- Gliomas
Intervention / Treatment
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, United States, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, United States, 30322
- Emory University Winship Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must have a clinically documented primary brain tumor for which resection is clinically indicated. Individuals with suspected newly diagnosed or recurrent malignant gliomas will be considered eligible for the study. The anticipated histology at resection should include: Anaplastic astrocytoma (10002224), Anaplastic ependymoma, Anaplastic oligodendroglioma, Astrocytoma malignant NOS (10003572), Glioblastoma (10018336), Glioblastoma multiforme (10018337), or Gliosarcoma (10018340).
- Prior therapy is not a consideration in protocol entry.
- Age 18-80.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%).
- Life expectancy is not a consideration for protocol entry.
Subjects must have normal organ and marrow function as defined below:
- Leukocytes ≥ 3,000/mL
- Platelets ≥ 100,000/mL
- Total bilirubin below upper limit of normal
- Aspartate aminotransferase (AST) (SGOT)/alanine aminotransferase (ALT) (SGPT) ≤ 2.5 X institutional upper limit of normal
- Creatinine below upper limit of normal OR
- Creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal
- The effects of aminolevulinic acid (ALA) on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A pregnancy test will be performed for all women of childbearing ability prior to surgery. Women who are pregnant will be excluded from the trial.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Tumors of or involving the midline, basal ganglia, or brain stem as assessed by MRI.
- Subjects may not be receiving any experimental therapies.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid (ALA). Patients should refrain from use of other potential phototoxic substances (e.g. tetracyclines, sulfonamides,fluoroquinolones, hypericin extracts) for 72 hours.
- Personal or family history of porphyrias.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant women are excluded from this study because aminolevulinic acid (ALA) is of unknown teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with aminolevulinic acid (ALA), breastfeeding should be discontinued if the mother is treated with aminolevulinic acid (ALA).
- Women who are pregnant will be excluded from the trial.
- Prior history of GI perforation, diverticulitis, and/or peptic ulcer disease.
- Inclusion of women and minorities: both men and women and members of all ethnic groups are eligible for this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 5-ALA (Gliolan)
Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
|
20 mg/kg administered once 3-5 hours prior to surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radicality of Brain Tumor Resection
Time Frame: Within the first 48 hours after surgery
|
Within the first 48 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival every 3 months after surgery
Time Frame: Every 3 months until tumor progression on MRI
|
Every 3 months until tumor progression on MRI
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Costas Hadjipanayis, MD, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Surgery
- 5-ALA
- Brain Tumors
- Glioblastoma
- Brain Cancer
- Fluorescence
- Benign Neoplasms, Brain
- Brain Neoplasms, Benign
- Brain Neoplasms, Malignant
- Brain Tumor, Primary
- Brain Tumor, Recurrent
- Intracranial Neoplasms
- Neoplasms, Brain
- Neoplasms, Intracranial
- Primary Brain Neoplasms
- Primary Malignant Brain Neoplasms
- Primary Malignant Brain Tumors
- Gliomas
- Aminolevulinic acid
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms
- Glioblastoma
- Recurrence
- Glioma
- Brain Neoplasms
- Photosensitizing Agents
- Dermatologic Agents
- Aminolevulinic Acid
Other Study ID Numbers
- GCO 15-2034
- WCI1999-11 (Other Identifier: Other)
- R01CA176659 (U.S. NIH Grant/Contract)
- R21CA186169 (U.S. NIH Grant/Contract)
- IRB00051663 (Other Identifier: Emory University)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on 5-ALA (Gliolan)
-
Sociedad de Lucha Contra el Cáncer del EcuadorNot yet recruitingGlioma | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Central Nervous System Neoplasms | Brain Tumor | High Grade Glioma | Glioma, Malignant | Neoplasm Malignant | Photosensitizing Agents | Tumour, Residual | Brain Neoplasms, Adult, MalignantEcuador
-
medac GmbHIKPCompleted
-
Constantinos HadjipanayisMassachusetts General HospitalCompletedMalignant GliomasUnited States
-
University of ZurichSwiss National Science FoundationUnknown
-
St. Joseph's Hospital and Medical Center, PhoenixUnknown
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Completed
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Completed
-
University of HawaiiSBI ALApromo Co., Ltd. - Strategic Business InnovatorCompletedStress | Insomnia | Irritability | Coping Behavior | Nocturnal AwakeningUnited States
-
Royal College of Surgeons in Ireland - Medical...Bahrain Defence Force HospitalWithdrawn
-
Royal College of Surgeons in Ireland - Medical...Bahrain Defence Force Hospital; Salmaniya Medical ComplexCompletedCOVID-19 | SARS-CoV 2Bahrain